首页 > 市场调查报告书 > 医疗设备

糖尿病

市场调查报告书

商品编码

1898206

糖尿病护理设备和药品市场规模、份额和成长分析（按类型、通路、最终用途和地区划分）—2026-2033年行业预测

Diabetes Care Devices and Drugs Market Size, Share, and Growth Analysis, By Type (BGM Devices, Insulin Delivery Devices), By Distribution Channel (Hospital pharmacies, Retail Pharmacies), By End-use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月17日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，糖尿病护理设备和药品市场规模将达到 325.6 亿美元，到 2025 年将达到 351.3 亿美元，到 2033 年将达到 645.5 亿美元，预测期（2026-2033 年）的复合年增长率为 7.9%。

糖尿病的特征是由于胰岛素分泌不足导致的高血糖症，仍然是全球面临的重大健康挑战。持续血糖监测设备在糖尿病管理中发挥着至关重要的作用，使患者能够轻鬆追踪全天的血糖值。糖尿病影响全球数百万人口，并带来许多重大风险，包括肾衰竭和心血管事件等併发症。由于肥胖率上升、久坐不动的生活方式以及大众对糖尿病的认知不足，中低收入国家的糖尿病盛行率尤其高。预计1型和2型糖尿病新诊断患者数量的持续成长将维持对糖尿病照护设备的需求。胰岛素输注系统的日益普及以及製造商为拓展治疗方案和改善糖尿病管理患者预后而不断进行的创新努力，进一步推动了这一需求。

糖尿病护理设备和药品市场成长要素

糖尿病照护设备和药品市场的成长主要受到旨在改善糖尿病管理的创新产品不断涌现的显着影响。糖尿病监测系统和治疗设备的进步推动了这一市场扩张，例如，目前正在进行的研究探索了诸如含胰岛素奈米颗粒涂层等增强口服胰岛素递送的方法。此外，研发投入的增加以及各相关人员之间的合作预计将进一步推动市场成长。这种充满活力的环境鼓励开发先进解决方案，最终改善患者预后并推动市场需求。

糖尿病照护设备和药品市场面临的限制

糖尿病照护设备和药品市场的成长可能受到多种因素的阻碍，例如某些地区报销政策不完善和监管严格。此外，与糖尿病密切相关的肥胖症日益增多，也对市场扩张构成挑战。同时，尤其是在开发中国家，人们对糖尿病诊断和治疗方案的认知严重不足，进一步阻碍了市场的潜在发展。这些问题迭加在一起，构成了阻碍全球糖尿病照护解决方案整体进步和发展的重大障碍。

糖尿病护理设备和药品市场趋势

糖尿病照护设备和药品市场正处于积极的成长轨道上，这主要得益于人们对糖尿病管理的认识和关注度不断提高，尤其是在新冠疫情等健康挑战的背景下。糖尿病患者被认为感染风险更高，这显着增加了对监测设备和居家治疗方案的需求。这一趋势反映出人们对远端医疗解决方案的日益青睐，从而提升了患者的自主性和治疗依从性。此外，个人化医疗领域的技术创新和进步也持续推动着市场发展，塑造出一个充满活力且不断演变的市场格局，其核心在于改善病患的治疗效果和生活品质。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Novo Nordisk（Denmark）
Medtronic（Ireland）
Abbott Laboratories（United States）
Johnson & Johnson（United States）
Biocon（India）
Eli Lilly and Company（United States）
Roche（Switzerland）
Bayer（Germany）
Dexcom（United States）
Insulet Corporation（United States）
Tandem Diabetes Care（United States）
Ascensia Diabetes Care（Switzerland）
Terumo Corporation（Japan）
Becton, Dickinson and Company（United States）
AstraZeneca（United Kingdom）
Pfizer（United States）
Merck & Co.（United States）
GlaxoSmithKline（United Kingdom）
McKesson Corporation（United States）

结论与建议

简介目录

Product Code: SQMIG35G2119

Diabetes Care Devices and Drugs Market size was valued at USD 32.56 Billion in 2024 and is poised to grow from USD 35.13 Billion in 2025 to USD 64.55 Billion by 2033, growing at a CAGR of 7.9% during the forecast period (2026-2033).

Diabetes remains a critical global health challenge, characterized by inadequate insulin production leading to elevated blood glucose levels. Continuous glucose monitors, pivotal in diabetes management, enable patients to track their glucose levels effortlessly throughout the day. With millions affected worldwide, diabetes poses significant risks, including complications such as kidney failure and cardiovascular events. The prevalence is particularly prominent in low- and middle-income nations, attributed to rising obesity rates, sedentary lifestyles, and limited awareness. The upward trend in newly diagnosed type 1 and type 2 diabetes cases is projected to sustain demand for diabetes care devices. This demand is further fueled by the increasing adoption of insulin delivery systems and manufacturers' commitment to innovation, enhancing treatment options and improving patient outcomes in diabetes management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Diabetes Care Devices and Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Diabetes Care Devices and Drugs Market Segments Analysis

Global Diabetes Care Devices and Drugs Market is segmented by Type, Distribution Channel, End-use and region. Based on Type, the market is segmented into BGM Devices and Insulin Delivery Devices. Based on Distribution Channel, the market is segmented into Hospital pharmacies, Retail Pharmacies, Diabetes Clinics/Centers, Online Pharmacies and Others. Based on End-use, the market is segmented into Hospitals, Diagnostic Centers and Homecare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Diabetes Care Devices and Drugs Market

The growth of the diabetes care devices and drugs market is significantly influenced by the continuous introduction of innovative products aimed at improving diabetes management. Advancements in diabetes monitoring systems and treatment devices contribute to this expansion, as evidenced by ongoing research initiatives exploring methods like coating insulin-loaded nanoparticles to enhance oral insulin delivery. Furthermore, heightened investments in research and development, alongside collaborative efforts among various stakeholders, are expected to foster additional opportunities for market growth. This dynamic environment encourages the creation of advanced solutions, ultimately improving patient outcomes and driving market demand.

Restraints in the Diabetes Care Devices and Drugs Market

The growth of the diabetes care devices and drugs market may be hindered by various factors, including inadequate reimbursement policies and strict regulations in certain regions. Additionally, the increasing prevalence of obesity, which is closely linked to diabetes, poses challenges for market expansion. Moreover, a significant lack of awareness regarding diabetes diagnosis and treatment options, particularly in developing countries, further obstructs the potential advancement of this market. These combined issues create substantial obstacles that could impede the overall progress and development of diabetes care solutions across the globe.

Market Trends of the Diabetes Care Devices and Drugs Market

The Diabetes Care Devices and Drugs market is experiencing a positive trajectory driven by heightened awareness and concern about managing diabetes, particularly in the context of health challenges like the coronavirus. As individuals with diabetes are recognized as being at increased risk, there has been a substantial surge in demand for monitoring devices and therapeutic solutions that facilitate at-home management. This trend reflects a growing preference for remote healthcare solutions, enhancing patient autonomy and adherence to treatment regimens. Additionally, innovations in technology and personalized medicine continue to fuel advancements, creating a dynamic and evolving market landscape focused on improved patient outcomes and quality of life.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Diabetes Care Devices and Drugs Market Size by Type & CAGR (2026-2033)

Market Overview
BGM Devices
- Self-Monitoring Devices
- Blood Glucose Meters
- Testing Strips
- Lancets
- Continuous Glucose Monitoring Devices
- Sensors
- Transmitters
- Receiver
Insulin Delivery Devices
- Pumps
- Pens
- Syringes and Needles
- Jet Injectors

Global Diabetes Care Devices and Drugs Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital pharmacies
Retail Pharmacies
Diabetes Clinics/Centers
Online Pharmacies
Others

Global Diabetes Care Devices and Drugs Market Size by End-use & CAGR (2026-2033)

Market Overview
Hospitals
Diagnostic Centers
Homecare

Global Diabetes Care Devices and Drugs Market Size & CAGR (2026-2033)

North America (Type, Distribution Channel, End-use)
- US
- Canada
Europe (Type, Distribution Channel, End-use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Distribution Channel, End-use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Distribution Channel, End-use)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Distribution Channel, End-use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Novo Nordisk (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocon (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dexcom (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Insulet Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tandem Diabetes Care (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ascensia Diabetes Care (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Terumo Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
McKesson Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments